-
公开(公告)号：US20210012905A1
公开(公告)日：2021-01-14
申请号：US17033681
申请日：2020-09-26
Inventor： KEIKO YUGAWA
Abstract: A method for evaluating an infection risk includes calculating a first infection risk value, which indicates a degree of an infection risk that a child is infected with an infectious disease, on the basis of infection information regarding family members, prevalence information regarding the infectious disease in organizations to which the family members belong, and one or more first infection risk coefficients, calculating, on the basis of the first infection risk value, a second infection risk value, which indicates a degree of the child's infection risk of being infected in a group at a children's facility, and performing first evaluation, in which the infection risk that the child is infected is evaluated on the basis of the first infection risk value, and second evaluation, in which the child's infection risk of being infected in the group is evaluated on the basis of the second infection risk value.
-
2.发明申请公开(公告)号：US20200062828A1
公开(公告)日：2020-02-27
申请号：US16513750
申请日：2019-07-17
Inventor： KEIKO YUGAWA
IPC: C07K16/10 , G01N33/569
Abstract: Provided is a dimer antibody including two structural domains independently each represented by the following amino acid sequence, in an N- to C-direction, N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-C wherein the antibody is capable of binding to a norovirus; FR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence; any one of the following requirements (i)-(iii) is satisfied. Requirement (i): the CDR1 includes an amino acid sequence having a sequence identity of not less than 60% with any one of the amino acid sequences represented by SEQ ID NO: 1-SEQ ID NO: 6, the CDR2 includes an amino acid sequence having a sequence identity of not less than 60% with any one of the amino acid sequences represented by SEQ ID NO: 7-SEQ ID NO: 12, and the CDR3 includes an amino acid sequence having a sequence identity of not less than 60% with any one of the amino acid sequences represented by SEQ ID NO: 13-SEQ ID NO: 17; Requirement (ii): the CDR1 includes an amino acid sequence in which one-three amino acid(s) of any one of the amino acid sequence represented by SEQ ID NO: 1-SEQ ID NO: 6 has/have been substituted, deleted, or added, the CDR2 includes an amino acid sequence in which one-three amino acid(s) of any one of the amino acid sequence represented by SEQ ID NO: 7-SEQ ID NO: 12 has/have been substituted, deleted, or added, and the CDR3 includes an amino acid sequence in which one-three amino acid(s) of any one of the amino acid sequence represented by SEQ ID NO: 13-SEQ ID NO: 17 has/have been substituted, deleted, or added; and Requirement (iii): the CDR1 includes any one of the amino acid sequence represented by SEQ ID NO: 1-SEQ ID NO: 6, the CDR2 includes any one of the amino acid sequence represented by SEQ ID NO: 7-SEQ ID NO: 13, and the CDR3 includes any one of the amino acid sequence represented by SEQ ID NO: 13-SEQ ID NO: 17.
-
Patent Agency Ranking
公开(公告)号：US20230414166A1
公开(公告)日：2023-12-28
申请号：US18464221
申请日：2023-09-10
Inventor： KEIKO YUGAWA , YUMIKO KATO , MOTOKI YAKO , ATSUSHI ISHIKAWA
CPC classification number: A61B5/444 , A61B5/7435 , A61B5/0077 , G06T7/0012 , G06T2207/30088
Abstract: A method for evaluating a user's skin condition, the method being performed by a computer, includes acquiring image data concerning part of the user's body and including information for four or more bands, determining an evaluation region in the part of the user's body in an image representing the part of the user's body in accordance with an input from the user, and generating, based on the image data, and outputting evaluation data representing an evaluation result of skin condition in the evaluation region.
-
4.发明申请公开(公告)号：US20200062829A1
公开(公告)日：2020-02-27
申请号：US16513752
申请日：2019-07-17
Inventor： KEIKO YUGAWA
IPC: C07K16/10 , G01N33/543 , G01N33/68 , B01L3/00 , G01N33/52
Abstract: The present invention provides an antibody including a structural domain represented by the following amino acid sequence, in an N- to C-direction, N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-C wherein the antibody further includes a protein molecule bound to the structural domain; the structural domain is capable of binding to a norovirus; FR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence; any one of the following requirements (i)-(iii) is satisfied. Requirement (i): the CDR1 includes an amino acid sequence having a sequence identity of not less than 60% with any one of the amino acid sequences represented by SEQ ID NO: 1-SEQ ID NO: 6, the CDR2 includes an amino acid sequence having a sequence identity of not less than 60% with any one of the amino acid sequences represented by SEQ ID NO: 7-SEQ ID NO: 12, and the CDR3 includes an amino acid sequence having a sequence identity of not less than 60% with any one of the amino acid sequences represented by SEQ ID NO: 13-SEQ ID NO: 17; Requirement (ii): the CDR1 includes an amino acid sequence in which one-three amino acid(s) of any one of the amino acid sequence represented by SEQ ID NO: 1-SEQ ID NO: 6 has/have been substituted, deleted, or added, the CDR2 includes an amino acid sequence in which one-three amino acid(s) of any one of the amino acid sequence represented by SEQ ID NO: 7-SEQ ID NO: 12 has/have been substituted, deleted, or added, and the CDR3 includes an amino acid sequence in which one-three amino acid(s) of any one of the amino acid sequence represented by SEQ ID NO: 13-SEQ ID NO: 17 has/have been substituted, deleted, or added; and Requirement (iii): the CDR1 includes any one of the amino acid sequence represented by SEQ ID NO: 1-SEQ ID NO: 6, the CDR2 includes any one of the amino acid sequence represented by SEQ ID NO: 7-SEQ ID NO: 13, and the CDR3 includes any one of the amino acid sequence represented by SEQ ID NO: 13-SEQ ID NO: 17.
-
公开(公告)号：US20240422443A1
公开(公告)日：2024-12-19
申请号：US18822361
申请日：2024-09-02
Inventor： KEIKO YUGAWA , MOTOKI YAKO
Abstract: An imaging system includes a light source, an imaging apparatus that captures an image of a subject illuminated by light from the light source to generate image data, which includes image information regarding each of four or more bands or information regarding a compressed image in which the image information regarding the four or more bands is compressed as a single image, and a processing apparatus. The processing apparatus determines whether or not pixel values of pixels in the image data satisfy a predetermined condition, and causes, in a case where the predetermined condition is not satisfied, a lighting condition caused by the light source to be changed under a condition where a spectral shape of light from the light source does not change at the subject's location.
-
6.发明申请公开(公告)号：US20190002535A1
公开(公告)日：2019-01-03
申请号：US15979950
申请日：2018-05-15
Inventor： KEIKO YUGAWA
IPC: C07K16/10 , G01N33/569
CPC classification number: C07K16/10 , C07K2317/22 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/92 , G01N33/56983 , G01N2800/06
Abstract: The present invention provides a novel antibody capable of binding to a norovirus. The present invention is an antibody that consists of an amino acid sequence, wherein said amino acid sequence consists of, in an N- to C-direction, the following structural domains: N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-C wherein FR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence; the CDR1 consists of any one of an amino acid sequences represented by SEQ ID NO: 1-SEQ ID NO: 6; the CDR2 consists of any one of an amino acid sequences represented by SEQ ID NO: 7-SEQ ID NO: 12; the CDR3 consists of any one of an amino acid sequences represented by SEQ ID NO: 13-SEQ ID NO: 17; and the antibody is capable of binding to a norovirus.
-
公开(公告)号：US20170283485A1
公开(公告)日：2017-10-05
申请号：US15388196
申请日：2016-12-22
Inventor： KEIKO YUGAWA , JIN MURAOKA , JUNKO MURAOKA , HIROSHI NAKAYAMA
IPC: C07K16/10
CPC classification number: C07K16/1018 , C07K2317/22 , C07K2317/569 , C07K2317/92
Abstract: The present invention provides a novel antibody capable of binding influenza virus. The antibody directed to the present invention consists of an amino acid sequence, wherein said amino acid sequence consists of, in an N- to C-direction, the following structural domains: N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-C FR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence; the CDR1 consists of an amino acid sequence represented by SYYMS (SEQ ID NO: 01) the CDR2 consists of an amino acid sequence represented by TINTGGGSTYYADSVKG (SEQ ID NO: 02); the CDR3 consists of an amino acid sequence represented by DGPYGGYDY (SEQ ID NO: 03); and the antibody is capable of binding to H12N1 influenza virus. Desirably, the FR1-FR4 consist of amino acid sequences represented by EVQLVESGGGLVQPGGSLRVSCAASGFTFS (SEQ ID NO: 04), WVRQAPGKGLEWVS (SEQ ID NO: 05), RFTISRDNAKNTLYLQMDSLKSEDTAVYYCAK (SEQ ID NO: 06), and WGQGTQVTVSP (SEQ ID NO: 07), respectively.
-
-
-
-
-
-
Search Results
7
records
(took 0.017 seconds)
